Literature DB >> 30867776

Comparison of the effects of sevoflurane and propofol anesthesia on pulmonary function, MMP-9 and postoperative cognition in patients receiving lung cancer resection.

Guan Wang1, Jie Liu1, Jinxia Gao1, Xin Zheng2.   

Abstract

Effects of sevoflurane and propofol anesthesia on pulmonary function, matrix metalloproteinase-9 (MMP-9) and postoperative cognition were compared in patients undergoing simple resection of lower lobe of left lung. Retrospective method was used to analyze 58 cases of lung cancer patients treated by simple resection of lower lobe of left lung in the Second Hospital of Dalian Medical University from October 2016 to October 2017, and they were divided into two groups: Sevoflurane group (n=32) with sevoflurane anesthesia and propofol group (n=26) with propofol anesthesia. In the present study, the moment before induction of anesthesia (T1), before the start of one-lung ventilation (T2), before the end of one-lung ventilation (T3), after closed chest surgery (T4), 24 h after surgery (T5), calculate alveolar-arterial oxygen difference (A-aDO2), respiratory index (RI) and intrapulmonary shunt ratio (Qs/Qt), were compared between the two groups. The serum MMP-9 concentration at T1, T4 and T5 were detected by enzyme linked immunosorbent assay. The cognitive function of two groups was assessed by Mini-Mental State Examination (MMSE) 1 day before surgery and 1 and 10 days after surgery. The A-aDO2 level at T4 in sevoflurane group was significantly higher than that in propofol group (P<0.05). The RI level at T3, T4, the Qs/Qt and the MMP-9 level at T4 in the sevoflurane group was significantly higher than that in the propofol group (P<0.05). The MMSE score in sevoflurane group was significantly lower than that in propofol group 1 and 10 days after surgery (P<0.05). Propofol has little effect on pulmonary function and can decrease inflammatory factor MMP-9. Both sevoflurane and propofol have an effect on cognitive function after lung cancer resection, but propofol can reduce cognitive impairment in patients with lung cancer.

Entities:  

Keywords:  MMP-9; cognitive function; lung cancer resection; propofol; pulmonary function; sevoflurane

Year:  2019        PMID: 30867776      PMCID: PMC6396185          DOI: 10.3892/ol.2019.9993

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Lung cancer has the highest morbidity and mortality rate in the male population and the second highest in the female population among the common malignant tumors in the world (1). There are about 1.8 million new cases of lung cancer and 1.6 million deaths in the world every year, and the 5-year survival rate is only 15% (2,3). The risk factors for lung cancer include industrial pollution, air pollution, genetic factors, and smoking (4). Lung cancer resection is one of the most important methods in the treatment of early lung cancer in clinic. However, postoperative cognitive impairment is a problem that clinicians have always been trying to overcome. It has been proved that anesthesia can cause brain cognitive impairment, which can increase the recovery time and financial burden in mild cases and become life-threatening in severe cases (5,6). At the same time, it is easy to cause a certain degree of lung ischemia-reperfusion injury and affect the pulmonary function, thus affecting the prognosis of patients because of the need of resection of partial lung tissue after surgery (7). Serum matrix metalloproteinase-9 (MMP-9) is one of the proteolytic enzymes released by neutrophils. The release of MMP-9 by neutrophils is considered to play an important role in promoting pulmonary inflammation by degrading basement membrane and migrating neutrophils to lung tissues and airways (8). According to reports in the literature, some anaesthetics have effects of cell protection and are anti-inflammatory (9). Therefore, how to improve anesthetic methods and reduce the malignant effects of anesthesia on pulmonary function and cognitive function is a very important issue. The purpose of this study was to compare the effects of sevoflurane and propofol anesthesia on pulmonary function, MMP-9 and postoperative cognition in patients undergoing simple resection of the lower lobe of left lung, and to provide a theoretical basis for better clinical choice of anaesthetics.

Patients and methods

Basic information

A total of 58 cases of lung cancer treated by simple resection of lower lobe of left lung in the Second Hospital of Dalian Medical University (Dalian, China) from October 2016 to October 2017 were analyzed retrospectively, including 36 males and 22 females with an average age of 52.68±14.52 years. They were divided into two groups: Sevoflurane group (n=32) with sevoflurane anesthesia and propofol group (n=26) with propofol anesthesia. There was no significant difference in the basic information between the two groups (P>0.05). Pregnancy and lactation, autoimmune diseases, chronic inflammation, diabetes, hypertension and heart disease were excluded in all cases, and all patients had normal liver and kidney function and did not receive radiotherapy, chemotherapy, hormones and other drug analgesia, or anti-inflammatory treatment before surgery. The study was approved by the Ethics Committee of the Second Hospital of Dalian Medical University. Patients who participated in this research had complete clinical data. The signed informed consents were obtained from the patients or the guardians (Table I).
Table I.

Basic information [n (%)].

Groups

FactorsSevoflurane (n=32)Propofol (n=26)t/χ2P-value
Age (years)0.2880.782
  <5212 (37.50)  8 (30.77)
  ≥5220 (62.50)18 (69.23)
Sex0.2200.787
  Male19 (59.38)17 (65.38)
  Female13 (40.62)  9 (34.62)
BMI (kg/m2)26.42±1.0525.84±1.171.9880.052
Operation duration (min)194.52±42.41195.83±45.610.1130.910
Revival time (min)22.15±8.2323.36±9.420.5220.604
Smoking status0.6200.543
  Used to smoke23 (71.88)21 (80.77)
  Never smoke  9 (28.12)  5 (19.23)
ASA classification1.1150.429
  I18 (56.25)11 (42.31)
  II14 (43.75)15 (57.69)
Degree of education0.1300.778
  Junior secondary school and below10 (31.25)  7 (26.92)
  Junior high school or above22 (68.75)19 (73.08)
Preoperative heart rate (time/min)78.23±9.1377.84±8.910.1640.871
Mean arterial pressure during operation (mmHg)  88.62±15.22  86.28±16.570.5600.578
Blood loss during operation (ml)102.56±34.85100.17±29.740.2770.783
Infusion volume during operation (ml)1,263.25±342.121,186.64±320.730.8720.387

Treatment methods

The patients were prohibited from eating for 8 h and using medication before the surgery, and 0.2 mg/kg midazolam intravenous injection (H20031037; Jiangsu Enhua Pharmaceutical Group Co., Ltd., Jiangsu, China) was conducted 30 min prior to surgery. Invasive monitoring of angiosthenia, central venous pressure, electrocardiogram, blood pressure, heart rate, pulse and oxygen protection was established. In propofol group, propofol (H20030114; Sichuan Guorui Pharmaceutical Co., Ltd., Sichuan, China) target-controlled infusion (plasma concentration 3 µg/ml), 3 µg/kg fentanyl (H20030197; Yichang Humanwell Pharmaceutical Co., Ltd., Yichang, China), and 0.3 mg/kg atracurium (H20060869; Jiangsu Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) rapidly induced endotracheal intubation by intravenous injection. After intubation, the flow of inhaled oxygen was 2.0 l/min, the tidal volume was 8–10 ml/kg, the respiratory rate was 10–12 times/min, and the respiratory ratio was 1:1.5. TCI pump (cp-660tci pump; Shanghai Huanxi Medical equipment Co., Ltd., Shanghai, China) propofol target controlled infusion (plasma concentration 4 µg/ml) was used to maintain anesthesia. In sevoflurane group, 6% sevoflurane (H35020148; Fujian Gutian Pharmaceutical Co., Ltd., Fujian, China) with 5 l/min oxygen flow was initially inhaled. The patients were asked to take a deep breath and applied positive pressure manual ventilation when their consciousness disappeared. The oxygen flow was reduced to 2 l/min, and the concentration of sevoflurane in the volatile tank was adjusted to maintain the end-expiratory sevoflurane concentration in the gas monitor at 1.0 MAC, fentanyl 3 µg/kg, atracurium 0.5–0.6 mg/kg rapidly induced endotracheal intubation by intravenous injection, and 3% sevoflurane was inhaled continuously for maintenance of anesthesia. Both groups received continuous infusion of atracurium and fentanyl with micro-infusion pump during surgery, and the average BIS was maintained between 40 and 60%.

Observation index

The moment before induction of anesthesia (T1), before the start of one-lung ventilation (T2), before the end of one-lung ventilation (T3), after closed chest surgery (T4), 24 h after surgery (T5), calculate alveolar-arterial oxygen difference (A-aD02), respiratory index (RI) and intrapulmonary shunt ratio (Qs/Qt) were compared between the two groups (10). The MMP-9 concentration in patients at T1, T4 and T5 was detected by ELISA (Shanghai Xinfan Biotechnology Co., Ltd., Shanghai, China). Then, 3 ml peripheral venous blood was drawn from all patients at T1, T4 and T5 and centrifuged with 3,000 × g for 8 min at 4°C. The serum was collected and the level of MMP-9 was detected by ELISA. The specific operation methods were strictly in accordance with the instructions. The cognitive function of two groups was assessed according to Mini-Mental State Examination (MMSE) 1 day before surgery and 1 and 10 days after surgery. The total score of MMSE is 30 points, and the normal range is 27–30 points. A decrease of 2 points is statistically significant. A total score of 23 or less can be diagnosed as POCD. In addition, the occurrence of restlessness in patients was recorded after surgery (11).

Statistical analysis

The data was analyzed by SPSS 20.0 statistical software (IBM Corp., Armonk, NY, USA). Chi-square test was used for count data. t-test was used for paired comparisons, and οne-way ANOVA was used for multiple comparisons. The repetitive measure analysis of variance (ANOVA) was used in the comparison of different times within the group with Least Significant Difference test. P<0.05 was considered to indicate a statistically significant difference.

Results

Comparison of pulmonary function between two groups

There was no significant difference in A-aDO2 level at T1, T2, T3, T5 between sevoflurane and propofol groups (P>0.05). The A-aDO2 level at T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher A-aDO2 level at T2, T3, T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly higher A-aDO2 level at T3 and T4 than that at T2, and both sevoflurane and propofol groups had significantly lower A-aDO2 level at T5 than that at T2. Both sevoflurane and propofol groups had significantly lower A-aDO2 level at T4 and T5 than that at T3. Both sevoflurane and propofol groups had significantly lower A-aDO2 level at T5 than that at T4, and the difference was statistically significant (P<0.05). There was no significant difference in RI level at T1, T2, T5 between sevoflurane and propofol groups (P>0.05). The RI level at T3, T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher RI level at T2, T3, T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly higher RI level at T3 and T4 than that at T2, and both sevoflurane and propofol groups had significantly lower RI level at T5 than that at T2. Both sevoflurane and propofol groups had significantly lower RI level at T4 and T5 than that at T3. Both sevoflurane and propofol groups had significantly lower RI level at T5 than that at T4, and the difference was statistically significant (P<0.05). There was no significant difference in Qs/Qt at T1, T5 between sevoflurane and propofol groups (P>0.05). The Qs/Qt at T2, T3 and T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher Qs/Qt at T2, T3, T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly higher Qs/Qt at T3 and T4 than that at T2, and both sevoflurane and propofol groups had significantly lower Qs/Qt at T5 than that at T2. Both sevoflurane and propofol groups had significantly lower Qs/Qt at T4 and T5 than that at T3. Both sevoflurane and propofol groups had significantly lower Qs/Qt at T5 than that at T4, and the difference was statistically significant (P<0.05; Fig. 1 and Table II).
Figure 1.

Comparison of pulmonary function between two groups. (A) There was no significant difference in A-aDO2 level at T1, T2, T3 and T5 between sevoflurane and propofol groups (P>0.05). The A-aDO2 level at T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher A-aDO2 level at T2, T3, T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly higher A-aDO2 level at T3 and T4 than that at T2, and both sevoflurane and propofol groups had significantly lower A-aDO2 level at T5 than that at T2. Both sevoflurane and propofol groups had significantly lower A-aDO2 level at T4 and T5 than that at T3. Both sevoflurane and propofol groups had significantly lower A-aDO2 level at T5 than that at T4, and the difference was statistically significant (P<0.05). (B) There was no significant difference in RI level at T1, T2 and T5 between sevoflurane and propofol groups (P>0.05). The RI level at T3 and T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher RI level at T2, T3, T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly higher RI level at T3 and T4 than that at T2, and both sevoflurane and propofol groups had significantly lower RI level at T5 than that at T2. Both sevoflurane and propofol groups had significantly lower RI level at T4, T5 than that at T3. Both sevoflurane and propofol groups had significantly lower RI level at T5 than that at T4, and the difference was statistically significant (P<0.05). (C) There was no significant difference in Qs/Qt at T1, T5 between sevoflurane and propofol group (P>0.05). The Qs/Qt at T2, T3 and T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher Qs/Qt at T2, T3, T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly higher Qs/Qt at T3 and T4 than that at T2, and both sevoflurane and propofol groups had significantly lower Qs/Qt at T5 than that at T2. Both sevoflurane and propofol groups had significantly lower Qs/Qt at T4 and T5 than that at T3. Both sevoflurane and propofol groups had significantly lower Qs/Qt at T5 than that at T4, and the difference was statistically significant (P<0.05). *P<0.05 compared with T1; #P<0.05 compared with T2; &P<0.05 compared with T3; △P<0.05 compared with T4; @P<0.05. A-aDO2, alveolar-arterial oxygen difference; RI, respiratory index; Qs/Qt, intrapulmonary shunt ratio.

Table II.

Comparison of pulmonary function between two groups.

IndexNo.T1T2T3T4T5FP-value
A-aDO2 (mmHg)
  Sevoflurane3223.56±1.72213.54±28.46[a]426.52±43.26[a,b]244.73±33.25[ac]26.49±1.93[ad]1201.00<0.05
  Propofol2623.41±1.47207.16±25.31[a]413.64±44.82[a,b]219.67±31.48[ac]25.64±1.75[ad]938.10<0.05
  t0.3520.8921.1102.9231.738
  P-value0.7260.3760.2720.0050.088
RI
  Sevoflurane320.26±0.020.52±0.08[a]2.06±0.33[a,b]0.82±0.13[ac]0.33±0.06[ad]639.90<0.05
  Propofol260.25±0.030.49±0.09[a]1.82±0.24[a,b]0.71±0.12[ac]0.34±0.07[ad]616.10<0.05
  t1.5171.3433.1003.3160.586
  P-value0.1350.1850.0030.0020.560
Qs/Qt (%)
  Sevoflurane328.92±1.2412.68±1.72[a]24.56±3.17[a,b]15.28±1.93[ac]9.43±1.92[ad]294.10<0.05
  Propofol268.67±1.5210.93±1.74[a]20.73±2.73[a,b]13.15±1.62[ac]9.34±1.75[ad]167.50<0.05
  t0.6903.8344.8654.4860.185
  P-value0.493<0.05<0.05<0.050.854

P<0.05 compared with T1

P<0.05 compared with T2

P<0.05 compared with T3

P<0.05 compared with T4. A-aDO2, alveolar-arterial oxygen difference; RI, respiratory index; Qs/Qt, intrapulmonary shunt ratio

Comparison of MMP-9 between the two groups

There was no significant difference in MMP-9 level at T1 and T5 between sevoflurane and propofol group (P>0.05). The MMP-9 level at T4 in the sevoflurane group was significantly higher than that in the propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher MMP-9 level at T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly lower MMP-9 level at T5 than that at T4, and the difference was statistically significant (P<0.05; Fig. 2 and Table III).
Figure 2.

Comparison of MMP-9 between the two groups. There was no significant difference in MMP-9 level at T1 and T5 between sevoflurane and propofol groups (P>0.05). The MMP-9 level at T4 in the sevoflurane group was significantly higher than that in the propofol group, the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher MMP-9 level at T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly lower MMP-9 level at T5 than that at T4, and the difference is statistically significant (P<0.05). *P<0.05 compared with T1; #P<0.05 compared with T4; @P<0.05. MMP-9; matrix metalloproteinase-9.

Table III.

Comparison of MMP-9 between the two groups.

IndexNo.T1T4T5FP-value
MMP-9 (ng/ml)
  Sevoflurane32100.26±14.85186.72±19.42[a]114.56±15.61[a,b]245.100<0.05
  Propofol26102.14±13.76167.25±14.73[a]109.68±15.26[a,b]154.800<0.05
  t0.4954.2181.196
  P-value0.622<0.050.237

P<0.05 compared with T1

P<0.05 compared with T4. MMP-9, matrix metalloproteinase-9

Comparison of cognitive function between the two groups

There was no significant difference in MMSE score between sevoflurane and propofol groups 1 day before surgery (P>0.05). The MMSE score in sevoflurane group was significantly lower than that in propofol group 1 and 10 days after surgery, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly lower MMSE score of 1 and 10 days after surgery than that of 1 day before surgery. Both sevoflurane and propofol groups had significantly higher MMSE score of 10 days after surgery than that of 1 day after surgery, and the difference was statistically significant (P<0.05; Fig. 3 and Table IV).
Figure 3.

Comparison of cognitive function between the two groups. There was no significant difference in MMSE score between sevoflurane group and propofol group 1 day before surgery (P>0.05). The MMSE score in sevoflurane group was significantly lower than that in propofol group 1 and 10 days after surgery, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly lower MMSE score of 1 and 10 days after surgery than that of 1 day before surgery. Both sevoflurane and propofol groups had significantly higher MMSE score of 10 d after surgery than that of 1 day after surgery, and the difference was statistically significant (P<0.05). *P<0.05 compared with 1 day before surgery; #P<0.05 compared with 1 day after surgery; @P<0.05; MMSE, Mini-Mental State Examination.

Table IV.

Comparison of cognitive function between the two groups.

IndexNo.1 day before surgery1 day after surgery10 day after surgeryFP-value
MMSE score
  Sevoflurane3228.86±1.1321.84±1.02[a]27.21±1.03[a,b]311.100<0.05
  Propofol2629.23±1.0524.86±1.08[a]28.65±1.18[a,b]147.700<0.05
  t1.29010.8604.889
  P-value0.202<0.05<0.05

P<0.05 compared with 1 day before surgery

P<0.05 compared with 1 day after surgery. MMSE, Μini-Μental State Examination

Discussion

According to literature reports, A-aDO2 and RI are the main indicators of pulmonary diffusion function. There is a positive correlation between the index value and the degree of lung injury. The larger the value is, the more serious the lung injury is (12). Qs/Qt is associated with planing defects, causing arterial blood flow into the pulmonary vein to cause Qs/Qt to rise (13). MMP-9 is a proteolytic enzyme that activates inflammatory mediators and cells in the lung and increases the permeability of pulmonary capillaries, which leads to pneumonedema (14). The total score of MMSE is 30 points and less than 23 points are regarded as cognitive dysfunction (15). Propofol is the most widely used intravenous anesthesia in clinical surgical treatment and has the function of antioxidation and inhibition of inflammation. It is generally more stable when inducing anesthesia and rarely irritation symptoms appear (16). Sevoflurane is a new type of inhaled anesthesia with no irritation of upper respiratory tract, low inhibition of respiration, rapid recovery after surgery and short recovery time (17). Pulmonary lobectomy often results in patients breathing only through one lobe. Currently, hypoxic pulmonary vasoconstriction of non-ventilated lung is an important factor affecting arterial partial pressure of oxygen. Therefore, A-aDO2, RI and Qs/Qt can be used as indicators for evaluating pulmonary function of patients (18). In this study, there was no significant difference in the clinical data of patients (P>0.05), thus the data was comparable. The A-aDO2 level at T4 in sevoflurane group was significantly higher than that in propofol group, the difference was statistically significant (P<0.05). The RI level at T3 and T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). The Qs/Qt level at T2 and T3 and T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). The MMP-9 level at T4 in the sevoflurane group was significantly higher than that in the propofol group, and the difference was statistically significant (P<0.05). Combined with the above results, the lung injury of patients undergoing lung cancer resection with propofol was lower than that of sevoflurane, especially at T4. The level of A-aDO2, RI, Qs/Qt and MMP-9 in the serum of the patients of the two groups showed a trend of first increase and then decrease, but the level of A-aDO2, Qs/Qt and MMP-9 in propofol group was significantly lower than that in sevoflurane group. Findings of Tian et al (19) were basically consistent with ours, possibly because inhalation of sevoflurane released inflammatory mediators and made inflammatory cytokines highly expressed, leading to more severe lung injury in patients (20). Other studies have shown that inhalation of anaesthesia may cause reversible pulmonary alveolar fluid and a decrease of lung water clearance by affecting biomembrane, leading to perioperative pulmonary edema and thus affecting oxygen diffusion function (21). Animal experiments have shown that inhalation of anaesthesia can inhibit type II alveolar epithelial cells (AECII) from synthetizing pulmonary surfactant or decrease their activities (22). MMSE scale is one of the most important evaluation indicators, which has the advantages of simple operation, high efficiency and high reliability (23). Especially, lung cancer resection impairs the cognitive function of patients to a certain extent. Under the influence of surgical resection of lung tissue, lung cancer resection can reduce the ratio of ventilation volume to blood flow to a certain extent, resulting in hypoxemia and impairment of cognitive function of patients (24). In this study, there was no significant difference in MMSE score between sevoflurane and propofol group 1 day before surgery (P>0.05). The MMSE score in sevoflurane group was significantly lower than that in propofol group 1 and 10 days after surgery, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly lower MMSE score of 1 and 10 days after surgery than that of day 1 before surgery. Both sevoflurane and propofol groups had significantly higher MMSE score of 10 days after surgery than that of 1 day after surgery, and the difference was statistically significant (P<0.05). Combined with the above results, it showed that the use of propofol was beneficial to the recovery of cognitive function in patients, which was consistent with the results of Jin et al (25). The reason may be that sevoflurane can make increased permeability of mitochondrial membrane, activity of oxygen free radical, and enzyme concentration of inducing apoptosis, leading to postoperative amnesia in patients (26). However, there are still some limitations in this study. We hope that in the future, the research can be further deepened, and additional univariate analysis can be performed to compare the relationship between each clinical parameter and the A-aDO2, RI, MMP-9 and MMSE scores, or the multivariate analysis involving each clinical parameter as an independent variable. In conclusion, propofol has little effect on pulmonary function and can reduce inflammation. Both sevoflurane and propofol have an effect on cognitive function after lung cancer resection. However, propofol can reduce cognitive impairment in patients, and provide theoretical basis for better clinical choice of anaesthesia.
  5 in total

1.  Effects of propofol and inhaled anesthetics on postoperative complications for the patients undergoing one lung ventilation: A meta-analysis.

Authors:  Jing Yang; Qinghua Huang; Rong Cao; Yu Cui
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

Review 2.  Pancreatic Cancer and Microenvironments: Implications of Anesthesia.

Authors:  Hou-Chuan Lai; Yi-Wei Kuo; Yi-Hsuan Huang; Shun-Ming Chan; Kuang-I Cheng; Zhi-Fu Wu
Journal:  Cancers (Basel)       Date:  2022-05-28       Impact factor: 6.575

3.  Role of Sevoflurane on Natural Killer Group 2, Member D-Mediated Immune Response in Non-Small-Cell Lung Cancer: An In Vitro Study.

Authors:  Soeun Jeon; Hae-Kyu Kim; Jae-Young Kwon; Seung-Hoon Baek; Hyun-Su Ri; Ho Jung Choi; Hae-Ryung Cho; Young Shin Lee; Joo-Young Kim; Jinsil Kim; Jaeho Bae; Hyeon-Jeong Lee
Journal:  Med Sci Monit       Date:  2020-11-03

4.  Propofol suppresses the progression of non‑small cell lung cancer via downregulation of the miR‑21‑5p/MAPK10 axis.

Authors:  Xinhua Wu; Xuebin Li; Guiping Xu
Journal:  Oncol Rep       Date:  2020-05-21       Impact factor: 3.906

5.  Effect of Intravenous Propofol and Inhaled Sevoflurane Anesthesia on Postoperative Spirometric Indices: A Randomized Controlled Trial.

Authors:  Mohammad Hajijafari; Leila Mehrzad; Fatemah Sadat Asgarian; Hossein Akbari; Mohammad Hossein Ziloochi
Journal:  Anesth Pain Med       Date:  2019-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.